.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

Future Leaders in Neurology
Spotlight: MS
Spotlight: NMOSD

Clinical FocusSee All >

Dementia/Alzheimer
Epilepsy
Headache/Migraine
Movement Disorders
Multiple Sclerosis
Neuromuscular
Sleep Medicine
Stroke

Video Series

Cure Connections
Insights
NeurologyLive Peer Exchange
News Network

Advertise
Contact Us
Editorial
Do Not Sell My Information
Terms and Conditions
Privacy
Advisory Board

AAN 2020 Annual Meeting: Epilepsy Highlights

EP. 1: GWPCARE5 Trial Update: Lennox Gastaut Syndrome

May 15th 2020

EP. 2: GWPCARE5 Trial Update: Dravet Syndrome

May 15th 2020

EP. 3: AAN 2020 Data: Neurostimulation and Adjunctive ZX008

May 15th 2020

EP. 4: AAN 2020 Clinical Trial Data: Uncontrolled Focal Seizures

May 15th 2020

EP. 5: Cannabidiol for Lennox-Gastaut Syndrome and Dravet Syndrome

May 15th 2020

EP. 6: Cannabidiol Treatment for Tuberous Sclerosis Complex

May 15th 2020

EP. 7: Fenfluramine for Sunflower Syndrome

May 15th 2020

EP. 8: Epilepsy Treatment Outlook

May 15th 2020

EP. 9: Long-Term Data for Cannabidiol in Lennox-Gastaut Syndrome

May 15th 2020

EP. 10: Long-Term Data for Cannabidiol in Dravet Syndrome

May 15th 2020